Month: July 2015

THE FOURTH HURDLE – CAN IT BE SIMPLIFIED?

Melbourne, Australia – While regulatory systems are well established within Asia-Pacific countries, formalised health technology assessment (HTA) based reimbursement systems are relatively new, yet rapidly evolving. Closer understanding of the different reimbursement processes within Asia-Pacific can allow for best-practice cross-pollination, leading

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

AUSTRALIA – CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA

London, UK – Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires

Posted in Health Policy Analyses Tagged with: , , ,

TREATMENT PREFERENCES FOR BLOOD THINNERS: COMPARISON BETWEEN PHYSICIANS AND PATIENTS WITH ATRIAL FIBRILLATION IN THE U.S. AND JAPAN

Hirosaki, Japan – Blood thinners (anticoagulants) are crucial in preventing strokes among patients with atrial fibrillation (AF) but are associated with increased risk of bleeding. As described in the article, “Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with

Posted in Preference-Based Assessments, Value in Health Regional Issues Tagged with: , , ,

THE PROBLEM OF REIMBURSEMENT FOR SINGLE-USE DEVICES IN ASIA-PACIFIC COUNTRIES

Seoul, South Korea – In Asia-Pacific countries, as elsewhere, less than 6% of total health care spending per capita is on medical devices, though these technologies often make critical contributions to the delivery of clinical and economic benefits to both

Posted in ISPOR News & Press, Policy Perspectives, Value in Health Regional Issues Tagged with: , , ,

ENSURING THE FUTURE FOR CHINA’S ESSENTIAL DRUG POLICY

New Orleans, LA, USA & Shandong, China – China is one of the few middle-income countries with higher pharmaceutical cost out of total health care spending. The primary purpose of China’s National Essential Drug Policy (NEDP) in year 2009 was

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

ASSURE SAFETY IN INTRAVENOUS MEDICATION USE IN CHINA

Beijing, China – Chinese inpatients have experienced overuse of intravenous medications, with a total of 10.4 billion infusion bottles for 1.3 billion Chinese people annually, approximately 8 infusion bottles per capita in 2009. However, few studies have yet been published

Posted in Comparative Effectiveness Research / Health Technology Assessment, ISPOR News & Press, Value in Health Regional Issues Tagged with: , , ,